Unlocking the potential of EphA2 with precision-guided cancer therapy: bicycle drug conjugates
Gavin Bennett1, Jitka Riedl2, Gemma Mudd2
1BicycleTx Ltd, Portway Building, Granta Park, Cambridge, CB21 6GS, UK. gavin.bennett@bicycletx.com.
No abstract available in PubMed .
More Related Videos
07:33Enhancing Chimeric Antigen Receptor-Extracellular Vesicles (CAR-EV) Technology: The Future of Cancer Therapy
Published on: September 19, 2025
14:20Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Site-Targeted Drug Delivery Systems: Polymeric Carriers
Mitogens and the Cell Cycle
Modified-Release Drug Delivery Systems: Site-Targeted
